Gastroparesis: when the stomach stops
Feeling full after just two bites, having nausea almost every day, or throwing up food eaten hours earlier has a name. This is the complete 2026 guide to understanding what is going on and what can be done.
In gastroparesis the stomach empties too slowly, even though nothing is blocking it.
TL;DR (quick summary)
What is it?
- • The stomach empties very slowly with no obstruction to explain it.
- • Key symptoms: fullness, early satiety, nausea and vomiting.
What is done?
- • Diagnosis with gastric emptying scintigraphy.
- • Step-by-step treatment: diet, drugs and, if needed, G-POEM.
Gastroparesis is a disorder in which the stomach "stops": it empties too slowly even though there is no plug or physical blockage stopping food from leaving. The result is that food stays inside longer than it should, and very characteristic symptoms appear. We are seeing it more and more often in the clinic, partly because it is now diagnosed better.
Quick index
What is gastroparesis?
A normal stomach is a muscle that grinds up food and pushes it little by little toward the intestine. In gastroparesis that emptying becomes very slow. The medical definition is exactly that: symptoms suggesting food is being retained in the stomach, with a test that shows delayed gastric emptying and no mechanical obstruction to explain it.
An important idea consolidated in recent years is that gastroparesis and functional dyspepsia (especially what is called "postprandial distress syndrome", i.e. discomfort after meals) are probably not two completely separate diseases, but rather form a single continuous spectrum of gastric neuromuscular dysfunction. In fact, a key study from the GpCRC consortium showed that in tertiary care both are virtually interchangeable syndromes, sharing clinical and pathological features. 10
Who does it affect? Real figures
The figures vary enormously depending on how it is measured, but some data help to put it in context:
- • The classic Olmsted County (Minnesota) study considered it an uncommon condition in the general population, with a clear predominance in women.5
- • More recent studies using large insurance databases report much higher figures, up to 267.7 cases per 100,000 people.6
- • A recent systematic review places the prevalence between 13.8 and 267.7 per 100,000 adults, depending on the method used.4
There are two clear messages: it affects women more often, and it is not a trivial nuisance: in the Olmsted study overall survival was lower than expected for age and sex, a reminder that it should be taken seriously. 5
Diabetes and gastroparesis
In people with diabetes the risk is higher. Over 10 years, gastroparesis develops in about 5.2% of those with type 1 diabetes, 1.0% of those with type 2, and only 0.2% of people without diabetes. The risk in type 1 diabetes is much higher than in the general population. 7
Causes: from diabetes to Ozempic
There are several recognized causes: diabetes; some medications (opioid painkillers, certain antidepressants, Parkinson's drugs, octreotide, some blood-pressure drugs); previous viral infections (rotavirus, norovirus); neurological diseases (Parkinson's, multiple sclerosis, spinal cord injury); causes after surgery; and diseases that affect the stomach tissue, such as amyloidosis or scleroderma. Even so, by far the most common cause is the idiopathic one, meaning no specific reason can be found. 13
The diabetic and idiopathic forms are very similar. The differences are small: in the idiopathic form, abdominal pain, early satiety and post-meal fullness tend to be a bit more prominent, while in the diabetic form more intense nausea and vomiting dominate, with even slower emptying in type 1 diabetes. 3
A hot topic: Ozempic, Wegovy and similar drugs
GLP-1 drugs for diabetes and obesity (semaglutide, tirzepatide) naturally slow down stomach emptying. That is why they can cause gastroparesis-like symptoms (nausea, fullness) and, in addition, they are an important point to consider before anesthesia, because of the risk that stomach contents pass into the lungs. 17
Because semaglutide takes time to clear (its half-life is around 7 days and it needs about 23 days to drop below 10% of the initial level), anesthesia societies already recommend protocols to stop it before a procedure. If you take one of these drugs, always mention it before an endoscopy or surgery. 18
Why does it happen? What we see under the microscope
Thanks to full-thickness biopsies of the stomach wall, we now understand much better what goes wrong. The most characteristic feature is the loss of the interstitial cells of Cajal (ICC), which act as the stomach's "pacemaker": they set the rhythm of the contractions. When they decrease, the stomach loses strength and coordination to push food along. 89
Three main mechanisms have been identified:
- • Loss of the pacemaker cells (ICC) and of stomach nerves, along with an increase in immune cells, in both the diabetic and idiopathic forms.9
- • Role of the immune system: certain "good" (anti-inflammatory) macrophages are lost, a change linked to the loss of the cells of Cajal.8
- • Involvement of the pylorus (the stomach's outlet valve): on biopsies, up to 70.5% of patients had loss of cells of Cajal at that level. This explains why pylorus-targeted treatments make sense.11
An important nuance: these microscopic changes do not correlate well with how strong the symptoms are, so biopsy is not yet used routinely for diagnosis. 9
Symptoms: how it feels
The cardinal symptoms are: fullness after meals, early satiety (you fill up right away), nausea, vomiting, bloating and abdominal pain. Nausea and vomiting usually dominate the picture, especially in the diabetic form. If you are interested in the bloating symptom, there is more information in the abdominal bloating post linked below. 1
This is no minor problem: it strongly affects quality of life, can lead to malnutrition and, overall, is associated with higher mortality. In the GpCRC consortium cohort, most patients (61%) had moderate disease, and around 22% had a severe form requiring nutritional support. 3
Beware of opioids
About 40% of patients were using opioids, in 60% of cases for abdominal pain. The problem is that opioids themselves slow down emptying, so they can create a vicious circle that worsens gastroparesis. 3
To measure symptoms objectively we use a validated questionnaire, the GCSI (Gastroparesis Cardinal Symptom Index), which helps put a number on the discomfort and check whether treatment is working. 1
Diagnosis: the test that confirms it
According to the reference guideline (ACG 2022), the diagnosis rests mainly on one test: 1
| Test | What it is for |
|---|---|
| Gastric emptying scintigraphy | Standard test. Measures how much solid food remains in the stomach over 3 or more hours. |
| Wireless motility capsule (WMC) | Valid alternative to scintigraphy. |
| Upper endoscopy | Essential beforehand, to rule out an obstruction that could explain the symptoms. |
| Radiopaque markers | Not recommended for this indication. |
The key is to check emptying for at least 3 hours: measuring for less time can underestimate the problem. The exact way to perform and standardize this test is still debated in the most recent literature. 12
Step-by-step treatment of gastroparesis
Treatment is stepwise: you start with the simplest measures and move up depending on the response. It combines dietary measures, drugs and, in selected cases, endoscopic treatments.
1. Diet and blood-sugar control
The basic advice is small, frequent meals, low in fat and tough fiber (the so-called "small-particle diet"), because fat and fiber slow emptying even more. In the diabetic form, good blood-sugar control helps reduce the risk of gastroparesis getting worse over time. 1
2. Drugs
The strongest synthesis is a network meta-analysis (Ingrosso, Ford et al., Gastroenterology 2023) that pooled 24 trials and nearly 2,900 patients. 12 The essentials:
- • Metoclopramide: the only FDA-approved drug. It carries an important warning and should not be used for more than 3 months in a row, due to the risk of neurological side effects. A nasal version improved symptoms in women with diabetes in one study.12
- • Domperidone: an oral alternative; it requires heart monitoring (QT interval). It is not approved in the US.12
- • Erythromycin: an antibiotic that also stimulates the stomach; useful mainly intravenously in hospital, but it loses effect with prolonged use.1
- • Prucalopride: it sped up emptying in one trial (4-hour retention of 22% vs 40% with placebo), although it did not improve symptoms as much.13
- • Antiemetics and neuromodulators: ondansetron and low-dose antidepressants for nausea and discomfort.12
3. Endoscopic treatment of the pylorus: G-POEM
G-POEM (endoscopic pyloromyotomy) is the most relevant advance of the last decade. It is a procedure with no skin incisions: using an endoscope, the stomach's outlet valve (the pylorus) is released so that food can pass through more easily. It connects directly with the POEM technique we use in other esophageal diseases.
The landmark trial (Martinek et al., Gut 2022), compared against a sham procedure, demonstrated its efficacy in severe and refractory gastroparesis. 14 As for durability, reviews report a success rate of around 61% at one year, with better results when nausea and vomiting predominate and when food retention at 4 hours is high. The most recent evidence in diabetic gastroparesis (Gastroenterology 2025) confirms its benefit and highlights the role of EndoFLIP, a probe that measures in real time whether the pylorus opening is adequate. 1516
If you want to go deeper, I have a dedicated post on gastroparesis treatment with G-POEM.
4. Other options in resistant cases
- • Botulinum toxin into the pylorus: widely used, although the trial evidence is limited.1
- • Gastric neurostimulator: in one trial it reduced refractory vomiting.1
- • Nutritional support (feeding tube) in severe cases with malnutrition.1
You can find more related topics in my gastrointestinal disorders area.
My approach in the clinic
Gastroparesis is one of those diagnoses that many patients carry around for a long time without a name: they have been told their nausea or bloating is "just nerves" and they have been through several appointments without an answer. My priority is to confirm the diagnosis with the right test (gastric emptying scintigraphy), rule out an obstruction with endoscopy and, from there, build a tailored plan.
When drugs and diet are not enough, G-POEM offers a real, minimally invasive alternative. Because of my dedication to advanced endoscopy and POEM-type techniques, I assess case by case who can benefit from this approach, and I support each patient through the decision, calmly explaining what to expect.
If you have had nausea, vomiting or a constant feeling of fullness for a while, we can study your case in depth.
Related reading (to complete the map)
A personal touch (yes, this is medicine too)
Behind every case of gastroparesis there is a person who has spent months, sometimes years, unable to eat normally. My commitment is to find the why, put a name to what they feel, and offer the best possible option — from diet to advanced endoscopy.
FAQ: quick questions about gastroparesis
What is gastroparesis in plain words?
It is a disorder in which the stomach empties too slowly even though nothing is physically blocking it. Because food stays inside longer than normal, you get early fullness, nausea, vomiting and bloating. 1
Can gastroparesis be cured, or is it managed for life?
It usually cannot be fully "cured", but in most people it is well controlled with diet, blood-sugar control if there is diabetes, and medication. In resistant cases, pylorus-targeted techniques such as G-POEM markedly improve symptoms. 14
Can Ozempic or Wegovy cause gastroparesis-like symptoms?
These GLP-1 drugs naturally slow down stomach emptying, so they can cause similar nausea and fullness. That is why you should tell your medical team before an endoscopy or surgery under anesthesia. 17
How is it diagnosed?
The reference test is gastric emptying scintigraphy, which measures how much food remains in the stomach over 3 or more hours. An endoscopy is done first to rule out any obstruction. 1
References (clickable)
- Camilleri M, Kuo B, Nguyen L, et al. ACG Clinical Guideline: Gastroparesis. Am J Gastroenterol (2022). PMID: 35926490 · doi:10.14309/ajg.0000000000001874
- Disorders of gastric motility. Lancet Gastroenterol Hepatol (2024). View article
- Pasricha PJ, et al. (GpCRC). Progress in Gastroparesis — A Narrative Review of the Work of the Gastroparesis Clinical Research Consortium. Clin Gastroenterol Hepatol (2022). PMC9691520 · doi:10.1016/j.cgh.2022.05.022
- Dilmaghani S, Zheng T, Camilleri M. Epidemiology and Healthcare Utilization in Patients With Gastroparesis: A Systematic Review. Clin Gastroenterol Hepatol (2023). PMID: 35870768
- Jung HK, Choung RS, Locke GR 3rd, et al. The incidence, prevalence, and outcomes of patients with gastroparesis in Olmsted County, Minnesota, from 1996 to 2006. Gastroenterology (2009). PMID: 19249393
- Ye Y, Yin Y, Huh SY, et al. Epidemiology, etiology, and treatment of gastroparesis: real-world evidence from a large US national claims database. Gastroenterology (2022). View article
- Choung RS, Locke GR 3rd, Schleck CD, et al. Risk of gastroparesis in subjects with type 1 and 2 diabetes in the general population. Am J Gastroenterol (2012). PMC3280088
- Grover M, et al. Gastric Biopsies in Gastroparesis: Insights into Gastric Neuromuscular Disorders to Aid Treatment. PMID: 32718570
- Grover M, Bernard CE, Pasricha PJ, et al. (GpCRC). Clinical-histological associations in gastroparesis: results from the Gastroparesis Clinical Research Consortium. Neurogastroenterol Motil (2012). PMID: 22339929
- Pasricha PJ, Grover M, Yates KP, et al. (GpCRC). Functional Dyspepsia and Gastroparesis in Tertiary Care are Interchangeable Syndromes With Common Clinical and Pathologic Features. Gastroenterology (2021). PMID: 33548234
- Depleted interstitial cells of Cajal and fibrosis in the pylorus: Novel features of gastroparesis. PMID: 26940535
- Ingrosso MR, Ford AC, et al. Efficacy and Safety of Drugs for Gastroparesis: Systematic Review and Network Meta-analysis. Gastroenterology (2023). View article
- Carbone F, Van den Houte K, Clevers E, et al. Prucalopride in Gastroparesis: A Randomized Placebo-Controlled Crossover Study. Am J Gastroenterol (2019). PMID: 31295161
- Martinek J, Hustak R, Mares J, et al. Endoscopic pyloromyotomy for the treatment of severe and refractory gastroparesis: a pilot, randomised, sham-controlled trial. Gut (2022). doi:10.1136/gutjnl-2022-326904
- Gastric Peroral Endoscopic Pyloromyotomy (G-POEM) Is Effective in the Treatment of Diabetic Gastroparesis: A Randomized, Double-Blinded, Sham-Controlled Trial. Gastroenterology (2025). View article
- Gastric Per-Oral Endoscopic Myotomy (G-POEM): Tips, Tricks, and Pitfalls. Curr Gastroenterol Rep (2024). View article
- Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide. J Clin Endocrinol Metab (2024). View article
- Shankar A, Sharma A, Vinas A, Chilton RJ. GLP-1 receptor agonists and delayed gastric emptying: implications for invasive cardiac interventions and surgery. Cardiovasc Endocrinol Metab (2024). PMID: 39649679
Think you might have gastroparesis? Let's study your case
I'll calmly explain which tests you need and which treatments — from diet to G-POEM — fit you best.
Book an Appointment